We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov). We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN). Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue. Source
No articles found.
Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the...
Intuitive Surgical, Inc. (Nasdaq:ISRG), headqua...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...
Arcturus Therapeutics is developing portfolio o...
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse p...
Oncternal Therapeutics is a clinical-stage onco...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.